Drugs / VRC-HIVDNA044-00-VP
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00801697 | Feb 2009 → Feb 2011 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00472719 | Aug 2007 → Jul 2008 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRC-HIVDNA044-00-VP | “4 mg VRC-HIVDNA044-00-VP administered as 1 mL” NCT00801697 ↗ |
| Modality | Vaccine | “experimental DNA HIV vaccine” NCT00472719 ↗ |
| Route | Other | “receive an injection of the VRC-HIVDNA044-00-VP vaccine at study entry and Months 1 and 2” NCT00472719 ↗ |